| scholarly article | Q13442814 |
| P50 | author | Percy A. Knolle | Q42845667 |
| Marc Ringelhan | Q47157724 | ||
| P2093 | author name string | Mathias Heikenwalder | |
| Klaus-Peter Janssen | |||
| Christian Kurts | |||
| Ulrich Nitsche | |||
| Natalio Garbi | |||
| Peter Brossart | |||
| Heidrun Gevensleben | |||
| Bastian Höchst | |||
| Linda Diehl | |||
| Annkristin Heine | |||
| Chrystel Flores | |||
| P2860 | cites work | Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 |
| Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents | Q28087754 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy? | Q29994573 | ||
| The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide | Q31144277 | ||
| A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells | Q33335471 | ||
| Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. | Q33474008 | ||
| Vaccine-induced myeloid cell population dampens protective immunity to SIV | Q33685961 | ||
| Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells | Q33873201 | ||
| Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects | Q34542239 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion | Q34715463 | ||
| Immature myeloid cells and cancer-associated immune suppression | Q34732381 | ||
| Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. | Q35050169 | ||
| Cancer and the gut microbiota: an unexpected link | Q35546934 | ||
| Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells | Q35740077 | ||
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Q35833921 | ||
| Chemokines: a new dendritic cell signal for T cell activation | Q35928287 | ||
| Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma | Q36069411 | ||
| Myeloid derived suppressor cells in human diseases | Q36338349 | ||
| Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness | Q36742295 | ||
| Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | Q36869774 | ||
| Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression | Q37295003 | ||
| Immunotherapy for advanced melanoma. | Q37301008 | ||
| Cross-priming in health and disease. | Q37760422 | ||
| Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment | Q37974937 | ||
| Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy | Q38548339 | ||
| Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance | Q39186289 | ||
| Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma | Q39830418 | ||
| Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. | Q40278531 | ||
| All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. | Q42605441 | ||
| Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. | Q43023367 | ||
| Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes | Q43800437 | ||
| Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer | Q43867070 | ||
| Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Q44017442 | ||
| Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients | Q46834848 | ||
| CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells | Q47686838 | ||
| Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. | Q54439509 | ||
| Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 | ||
| Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response | Q67589895 | ||
| Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell | Q79961154 | ||
| Efficient Treg depletion induces T-cell infiltration and rejection of large tumors | Q82437538 | ||
| Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC | Q82821037 | ||
| CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice | Q83201956 | ||
| P433 | issue | 8 | |
| P921 | main subject | tretinoin | Q29417 |
| P304 | page(s) | e1338995 | |
| P577 | publication date | 2017-06-16 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination | |
| P478 | volume | 6 |
| Q92731408 | Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells |
| Q58801064 | Retinoic Acid, Leaky Gut, and Autoimmune Diseases |
| Q90706071 | The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction |
Search more.